Get the Stockscreener App
1.68
4.02%
0.065
After Hours:
1.70
0.02
+1.19%
Alx Oncology Holdings Inc stock is traded at $1.68, with a volume of 1.14M.
It is up +4.02% in the last 24 hours and down -15.15% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.615
Open:
$1.62
24h Volume:
1.14M
Relative Volume:
1.44
Market Cap:
$221.10M
Revenue:
-
Net Income/Loss:
$-101.70M
P/E Ratio:
-0.886
EPS:
-1.8961
Net Cash Flow:
$-84.35M
1W Performance:
-11.35%
1M Performance:
-15.15%
6M Performance:
+1.20%
1Y Performance:
+208.14%
1-Day Range:
$1.605
$1.70
1-Week Range:
$1.60
$1.93
52-Week Range:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.68 | 212.55M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Mar-06-26 | Resumed | UBS | Buy |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX Oncology Holdings Inc. Appoints Jeff Knight As Chief Development And Operating Officer, Effective April 13, 2026 - marketscreener.com
Stock Market Recap: Is ALX Oncology Holdings Inc a stock for growth or value investorsTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer to Advance Cancer Therapy Pipeline 1 - Minichart
ALX Oncology names Jeff Knight as chief development officer By Investing.com - Investing.com South Africa
ALX Oncology names Jeff Knight as chief development officer - Investing.com
ALX Oncology Appoints Jeff Knight to Lead Development - TipRanks
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Bitget
Jeff Knight joins ALX Oncology (NASDAQ: ALXO) as development chief - Stock Titan
ALX brings in 30-year biotech veteran ahead of key cancer milestones - Stock Titan
Profit Recap: What are the risks of holding ALX Oncology Holdings Inc2026 Final Week & Trade Opportunity Analysis - baoquankhu1.vn
Retail Trends: Can ALX Oncology Holdings Inc reach all time highs this year2026 Market WrapUp & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Geopolitics Watch: Is ALX Oncology Holdings Inc attractive at current valuation2026 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Block Trades: Will ALX Oncology Holdings Inc benefit from government policyPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALXO Technical Analysis & Stock Price Forecast - Intellectia AI
RLMD Stock Surges 42% in a Week: Here's What You Should Know - Eastern Progress
Certain Common Stock of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Performance Based Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Recap Report: Is ALX Oncology Holdings Inc a stock for growth or value investors2026 Retail Activity & Free Reliable Trade Execution Plans - baoquankhu1.vn
ALX Oncology Holdings (ALXO) price target increased by 38.00% to 4.69 - MSN
RSI Check: Should I invest in ALX Oncology Holdings Inc before earningsWeekly Trade Report & Verified Short-Term Plans - baoquankhu1.vn
Risk Off: Can ALX Oncology Holdings Inc reach all time highs this year2026 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Buy Signal: What is ALX Oncology Holdings Incs book value per shareQuarterly Trade Summary & Weekly High Momentum Picks - baoquankhu1.vn
Investment Review: Is ALX Oncology Holdings Inc benefiting from interest rate changes2026 Trends & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock - MarketBeat
ALX Oncology (ALXO) CEO sells 12,311 shares to cover tax obligations - Stock Titan
ALX Oncology (ALXO) finance SVP sells 903 shares to cover tax bill - Stock Titan
Risk Recap: Is ALX Oncology Holdings Inc attractive at current valuation2026 Update & Capital Efficient Trading Techniques - baoquankhu1.vn
Earnings Recap: Will ALX Oncology Holdings Inc stock hit new highs in YEAR2026 Trade Ideas & Community Verified Watchlist Alerts - baoquankhu1.vn
Wells Fargo initiates coverage of ALX Oncology Holdings (ALXO) with overweight recommendation - MSN
ALXO: Wells Fargo Initiates Coverage with Overweight Rating | AL - GuruFocus
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO) - MarketBeat
Wells Fargo initiates ALX Oncology stock with overweight rating By Investing.com - Investing.com Canada
Wells Fargo Initiates ALX Oncology at Overweight With $5 Price Target - marketscreener.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
IBRX Stock Jumps on Progress in NK Cell Therapy Production - sharewise.com
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study - tradingview.com
RLMD stock surges 42% in a week: Here's what you should know - msn.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Finviz
ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart
ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):